Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus

Abstract

Objective: To determine the dose of triptorelin that is sufficient to maintain complete ovarian suppression in female patients with childhood-onset systemic lupus erythematosus (SLE) who require cyclophosphamide therapy, to determine the length of time needed to achieve ovarian suppression after initiation of triptorelin treatment, and to investigate the safety of triptorelin.

Methods: In this randomized, double-blind, placebo-controlled, dose-escalation study, female patients ages <21 years were randomized 4:1 to receive triptorelin (n = 25) or placebo (n = 6). The starting doses of triptorelin were 25, 50, 75, and 100 μg/kg, and the dose was escalated until complete ovarian suppression was maintained. The primary outcome was the weight-adjusted dose of triptorelin that provided complete ovarian suppression in at least 90% of the patients, as determined by gonadotropin-releasing hormone agonist stimulation testing. The secondary outcome was the period of time required to achieve ovarian suppression, as measured by unstimulated follicle-stimulating hormone and luteinizing hormone levels after the initiation of triptorelin treatment.

Results: Treatment with triptorelin at a weight-adjusted dose of 120 μg/kg body weight provided sustained complete ovarian suppression in 90% of the patients. After administration of the initial dose of triptorelin, 22 days were required to achieve complete ovarian suppression. The rates of adverse events (AEs) and serious adverse events (SAEs) per 100 patient-months of followup were not higher in the triptorelin group compared with the placebo group (for AEs, 189 versus 362; for SAEs, 2.1 versus 8.5).

Conclusion: High doses of triptorelin are needed to achieve and maintain complete ovarian suppression, but such doses appear to be well tolerated in adolescent female patients with childhood-onset SLE. Our data suggest that a lag time of 22 days after initiation of triptorelin treatment is required before cyclophosphamide therapy is started or continued.

Trial registration: ClinicalTrials.gov NCT00124514.

Conflict of interest statement

Conflict of Interest:

None of the authors perceive to have a conflict of interest relevant to the conduct of this study.

© 2015, American College of Rheumatology.

Figures

Figure 1

Patient disposition

Figure 2

Triptorelin Dosages for achieving Complete Ovarian Suppression (COS) Panel A. Weight-adjusted triptorelin dose for COS: To achieve COS pubertal girls with cSLE require widely varying dosages of triptorelin. To achieve COS in 90% of the girls 125 microgram/kg body weight were needed in the study population (purple line). Panel B. Weight-adjusted dose of triptorelin dose by Sexual Maturation. There is a large variation in weight-adjusted triptorelin dosing among girls with cSLE. ■ Bar shows average weight-adjusted dose of triptorelin for COS ■ Median weight-adjusted dose of triptorelin needed for COS ▲ Maximum weight-adjusted dose of triptorelin needed for COS Panel C. Days to COS as measured using suppressed FSH levels. Some females (n=3) maintained much suppressed FSH levels even after injection of triptorelin (Day 1). There may a trend of higher FSH levels after T3+4 dosing. When considering the entire population, 90% achieved suppressed unstimulated FSH levels (FSH < 2 mIU/mL) by Day 15, e.g. 2 weeks after the triptorelin injection Panel D. Days to COS as measured using suppressed LH levels. The number of days needed to achieve suppressed unstimulated levels of LH after injection of triptorelin (Day 1) does not seem to differ based on the dose of triptorelin. When considering the entire population, 90% achieved suppressed unstimulated LH levels (LH <1 mIU/mL) by Day 24, e.g. 23 days after the triptorelin injection.